Literature DB >> 16365399

Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes.

Zdenek Hel1, Wen-Po Tsai, Elzbieta Tryniszewska, Janos Nacsa, Phillip D Markham, Mark G Lewis, George N Pavlakis, Barbara K Felber, Jim Tartaglia, Genoveffa Franchini.   

Abstract

An HIV-1 vaccine able to induce broad CD4+ and CD8+ T cell responses may provide long-term control of viral replication. In this study we directly assess the relative benefit of immunization with vaccines expressing three structural Ags (Gag, Pol, and Env), three early regulatory proteins (Rev, Tat, and Nef), or a complex vaccine expressing all six Ags. The simultaneous administration of all six Ags during vaccination resulted in Ag competition manifested by a relative reduction of CD8+ T cell and lymphoproliferative responses to individual Ags. Despite the Ag competition, vaccination with all six Ags resulted in a delay in the onset and a decrease in the extent of acute viremia after mucosal challenge exposure to highly pathogenic SIV(mac251). Reduced levels of acute viremia correlated with lower post-set point viremia and long-term control of infection. In immunized animals, virus-specific CD4+ T cell and lymphoproliferative responses were preserved during acute viremia, and the maintenance of these responses predicted the long-term virological outcome. Taken together, these results suggest that the breadth of the immune response is probably more important than high frequency responses to a limited number of epitopes. These data provide the first clear evidence of the importance of nonstructural HIV Ags as components of an HIV-1 vaccine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16365399     DOI: 10.4049/jimmunol.176.1.85

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens.

Authors:  Mauro Pistello; Francesca Bonci; J Norman Flynn; Paola Mazzetti; Patrizia Isola; Elisa Zabogli; Valentina Camerini; Donatella Matteucci; Giulia Freer; Paolo Pelosi; Mauro Bendinelli
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.

Authors:  Thorsten Demberg; Ruth H Florese; Megan J Heath; Kay Larsen; Irene Kalisz; V S Kalyanaraman; Eun Mi Lee; Ranajit Pal; David Venzon; Richard Grant; L Jean Patterson; Birgit Korioth-Schmitz; Adam Buzby; Dilani Dombagoda; David C Montefiori; Norman L Letvin; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

Review 3.  Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".

Authors:  Kimberly A Schoenly; David B Weiner
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

4.  Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection.

Authors:  Ruth H Florese; Roger W Wiseman; David Venzon; Julie A Karl; Thorsten Demberg; Kay Larsen; Leon Flanary; V S Kalyanaraman; Ranajit Pal; Fausto Titti; L Jean Patterson; Megan J Heath; David H O'Connor; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  Vaccine       Date:  2008-04-30       Impact factor: 3.641

5.  DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge.

Authors:  Margherita Rosati; Cristina Bergamaschi; Antonio Valentin; Viraj Kulkarni; Rashmi Jalah; Candido Alicea; Vainav Patel; Agneta S von Gegerfelt; David C Montefiori; David J Venzon; Amir S Khan; Ruxandra Draghia-Akli; Koen K A Van Rompay; Barbara K Felber; George N Pavlakis
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-28       Impact factor: 11.205

6.  Antibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDS.

Authors:  Monica Vaccari; Rabih Halwani; L Jean Patterson; Adriano Boasso; Jennifer Beal; Elzbieta Tryniszewska; Anna Hryniewicz; David Venzon; Elias K Haddad; Mohamed El-Far; Margherita Rosati; George N Pavlakis; Barbara K Felber; Saleh Al-Muhsen; Marjorie Robert-Guroff; Rafick-Pierre Sekaly; Genoveffa Franchini
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

7.  Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure.

Authors:  Monica Vaccari; Brandon F Keele; Steven E Bosinger; Melvin N Doster; Zhong-Min Ma; Justin Pollara; Anna Hryniewicz; Guido Ferrari; Yongjun Guan; Donald N Forthal; David Venzon; Claudio Fenizia; Tia Morgan; David Montefiori; Jeffrey D Lifson; Chris J Miller; Guido Silvestri; Margherita Rosati; Barbara K Felber; George N Pavlakis; James Tartaglia; Genoveffa Franchini
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

8.  CD4+ T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIV(mac251) infection.

Authors:  M Vaccari; A Boasso; Z-M Ma; V Cecchinato; D Venzon; M N Doster; W P Tsai; G M Shearer; D Fuchs; B K Felber; G N Pavlakis; C J Miller; G Franchini
Journal:  Mucosal Immunol       Date:  2008-09-17       Impact factor: 7.313

9.  Reduced protection from simian immunodeficiency virus SIVmac251 infection afforded by memory CD8+ T cells induced by vaccination during CD4+ T-cell deficiency.

Authors:  Monica Vaccari; Joseph Mattapallil; Kaimei Song; Wen-Po Tsai; Anna Hryniewicz; David Venzon; Maurizio Zanetti; Keith A Reimann; Mario Roederer; Genoveffa Franchini
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

10.  Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239.

Authors:  Bin Jia; Sharon K Ng; M Quinn DeGottardi; Michael Piatak; Eloísa Yuste; Angela Carville; Keith G Mansfield; Wenjun Li; Barbra A Richardson; Jeffrey D Lifson; David T Evans
Journal:  PLoS Pathog       Date:  2009-01-23       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.